BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [PMID: 35071559 DOI: 10.12998/wjcc.v9.i36.11285]
URL: https://www.wjgnet.com/1007-9327/full/v9/i36/11285.htm
Number Citing Articles
1
Jose M. Huguet, Victor García-Lorenzo, Lidia Martí, Jose María Paredes, Jose Joaquin Ramírez, Miguel Pastor, Lucia Ruiz, Ana Sanahuja, Pilar Timoneda, Laura Sanchís, Gloria Alemany Pérez, Marta Maia Boscá-Watts. Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre StudyBiomedicines 2022; 10(9): 2130 doi: 10.3390/biomedicines10092130